Get the Stockscreener App
24.62
1.03%
0.25
After Hours:
24.62
Castle Biosciences Inc stock is traded at $24.62, with a volume of 196.05K.
It is up +1.03% in the last 24 hours and down -3.68% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
See More
Previous Close:
$24.37
Open:
$24.37
24h Volume:
196.05K
Relative Volume:
0.52
Market Cap:
$745.89M
Revenue:
$344.23M
Net Income/Loss:
$-24.16M
P/E Ratio:
-29.06
EPS:
-0.8471
Net Cash Flow:
$28.33M
1W Performance:
-2.26%
1M Performance:
-3.68%
6M Performance:
+9.37%
1Y Performance:
+16.96%
1-Day Range:
$24.37
$25.00
1-Week Range:
$21.79
$25.54
52-Week Range:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
24.62 | 738.31M | 344.23M | -24.16M | 28.33M | -0.8471 |
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences inks expansion at Nova Place - Yahoo Finance
After the close on May 6, Castle Biosciences will break down Q1 - Stock Titan
Castle Biosciences inks expansion at Nova Place on North SidePittsburgh Business Times - The Business Journals
Aug EndMonth: How sensitive is Castle Biosciences Inc to inflationShare Buyback & AI Enhanced Trading Signals - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Shares Down 7%What's Next? - MarketBeat
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year - Bitget
Castle Biosciences, Inc.Common stock (NQ: CSTL - The Chronicle-Journal
Castle Biosciences CEO sells shares worth $246,195 By Investing.com - Investing.com Australia
Breakouts Watch: Does Castle Biosciences Inc have declining or rising EPSEarnings Miss & Fast Gain Swing Alerts - baoquankhu1.vn
Ideas Watch: Can Castle Biosciences Inc deliver alphaWeekly Trade Report & AI Forecasted Stock Moves - baoquankhu1.vn
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 6,214 Shares of Stock - MarketBeat
Castle Biosciences CEO sells shares worth $246,195 - Investing.com
Castle Biosciences (CSTL) CEO pre-planned sale of 9,836 shares after option exercise - Stock Titan
Strong 2025 revenue and governance focus in Castle Biosciences (CSTL) proxy - Stock Titan
Castle Biosciences, Inc. (CSTL) stock price, news, quote and history - Yahoo Finance Singapore
Castle Biosciences, Inc. (CSTL) Stock Price, News, Quote & History - Yahoo! Finance Canada
AI Stocks: Can Castle Biosciences Inc maintain its current growth rate2026 Highlights & Daily Price Action Insights - baoquankhu1.vn
How Revenue Assumptions Are Rewriting The Story For Castle Biosciences (CSTL) - Yahoo Finance
CSTL PE Ratio & Valuation, Is CSTL Overvalued - Intellectia AI
CSTL SEC FilingsCastle Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Castle Biosciences CEO Maetzold sells shares worth $106,598 By Investing.com - Investing.com South Africa
Castle Biosciences CEO Maetzold sells shares worth $106,598 - Investing.com
Castle Biosciences (CSTL) CEO executes 10b5-1 share sales, exercises options - Stock Titan
Director at Castle Biosciences (CSTL) acquires 5,329 shares via RSUs - Stock Titan
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside (NASDAQ:CSTL) - Seeking Alpha
Castle Biosciences presents melanoma test data at AAD meeting By Investing.com - Investing.com Australia
Castle Biosciences Study Shows DecisionDx-Melanoma Test Enhances Risk Prediction Within AJCC Staging System - geneonline.com
Castle Biosciences presents melanoma test data at AAD meeting - investing.com
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - Newswise
Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - Bitget
Derek Maetzold reports multiple Rule 144 sales — CSTL (CSTL) - Stock Titan
Vanguard realigns reporting; holds 0% of Castle Biosciences (CSTL) - Stock Titan
Q4 2025 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Hedge Fund Moves: Can Castle Biosciences Inc deliver alpha2026 Top Decliners & High Return Trade Opportunity Guides - baoquankhu1.vn
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk - MarketBeat
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE StudySlideshow (NASDAQ:CSTL) 2026-03-23 - Seeking Alpha
Castle Biosciences Inc DecisionDx-Melanoma Call Transcript - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Valuation Update: Whats next for Castle Biosciences Inc stock2026 Retail & Weekly Hot Stock Watchlists - baoquankhu1.vn
Breakout Watch: Can Castle Biosciences Inc maintain its current growth rateMarket Performance Report & Safe Entry Point Identification - baoquankhu1.vn
What are the future prospects of Castle Biosciences IncWeekly Stock Report & Risk Controlled Daily Plans - baoquankhu1.vn
Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets - Yahoo Finance
Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock By Investing.com - Investing.com India
Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock - Investing.com
Derek Maetzold Sells 650 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 18,650 Shares of Stock - MarketBeat
Castle Biosciences (CSTL) CEO sells 19,300 shares under 10b5-1 plan - Stock Titan
Castle Biosciences introduces 487-gene panel to guide JAK inhibitor or Th2 therapy decisions - Traders Union
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Castle Biosciences Inc Stock (CSTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 06 '26 |
Sale |
25.03 |
6,214 |
155,536 |
21,479 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 06 '26 |
Sale |
25.03 |
3,622 |
90,659 |
2,780 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Mar 26 '26 |
Option Exercise |
2.39 |
550 |
1,314 |
22,029 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Mar 26 '26 |
Sale |
25.55 |
3,622 |
92,546 |
3,058 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Mar 26 '26 |
Sale |
25.55 |
550 |
14,053 |
21,479 |
1.41%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):